Australia markets close in 4 hours 56 minutes
  • ALL ORDS

    7,188.10
    -78.50 (-1.08%)
     
  • ASX 200

    6,989.60
    -75.60 (-1.07%)
     
  • AUD/USD

    0.6407
    -0.0010 (-0.15%)
     
  • OIL

    89.83
    +0.20 (+0.22%)
     
  • GOLD

    1,942.00
    +2.40 (+0.12%)
     
  • Bitcoin AUD

    41,501.41
    -666.25 (-1.58%)
     
  • CMC Crypto 200

    566.31
    -9.94 (-1.73%)
     
  • AUD/EUR

    0.6015
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0819
    +0.0009 (+0.08%)
     
  • NZX 50

    11,239.29
    -79.45 (-0.70%)
     
  • NASDAQ

    14,694.24
    -275.68 (-1.84%)
     
  • FTSE

    7,678.62
    -53.03 (-0.69%)
     
  • Dow Jones

    34,070.42
    -370.46 (-1.08%)
     
  • DAX

    15,571.86
    -209.73 (-1.33%)
     
  • Hang Seng

    17,655.41
    -230.19 (-1.29%)
     
  • NIKKEI 225

    32,240.56
    -330.47 (-1.01%)
     

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.